Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.

9 A slight trend of nonlinearity was observed at doses ≤1.0 mg/kg (Figure 3 ), possibly related to target‐mediated clearance at lower etrolizumab serum concentrations. 9 The slight nonlinearity of PK at doses ≤1.0 mg/kg resulted in shorter half‐lives at lower doses (4.8 to 7.4 days at 0.3 to 1 mg/kg) compared with longer half‐lives at higher doses (10.6 to 13.1 days at 3 to 10 mg/kg).

also in 4,078 other papers